Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.19.8475

Systematic Analysis of Pemetrexed-based Chemoradiotherapy for Patients with Locally Advanced or Metastatic Esophageal Cancer  

Tian, Guang-Yu (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Miu, Min (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.19, 2014 , pp. 8475-8478 More about this Journal
Abstract
Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of pemetrexed-based chemoradiotherapy in treating patients with locally advanced or metastatic esophageal cancer. Methods: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for relevant patients were identified using a predefined search strategy. Pooled response rates (RRs) were calculated. Results: For pemetrexed-based regimens, 4 clinical studies including 47 patients with locally advanced or metastatic esophageal cancer were considered eligible for inclusion. Systematic analysis showed that, in all patients, the pooled RR was 51% (24/47). Major adverse effects of grade III/IV were esophagitis, neutropenia, thrombocytopenia, anemia anorexia, fatigue, diarrhea, dysphagia and vomiting. No treatment related death occurred with pemetrexed-based treatment. Conclusion: This systematic analysis suggests that pemetrexed based radiotherapy is associated with reasonable activity and good tolerability in treating patients with locally advanced or metastatic esophageal cancer.
Keywords
Metastatic esophageal cancer; pemetrexed-based chemoradiotherapy; efficacy; tolerability;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Ajani JA, Ilson DH, Daugherty K, et al (1994). Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst, 86, 1086-91.   DOI   ScienceOn
2 Holmes FA, Valero V, Buzdar AU (1998). Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer: the long and the short of it. Proc Am Soc Clin Oncol, 17, 110a (Abstr 426).
3 Bhatt RS, Merchan J, Parker R, et al (2010). A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer, 116, 1751-6.   DOI
4 Bucci MK, Rosenthal DI, Hershock D, et al (2004). Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer. Am J Clin Oncol, 27, 595-602.   DOI
5 Herscher LL, Cook J (1999). Taxanes as radiosensitizers for head and neck cancer. Curr Opin Oncol, 11, 183-6.   DOI   ScienceOn
6 Jatoi A, Soori G, Foster NR, et al (2010). Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. J Thorac Oncol, 5, 1994-8.   DOI
7 Katipamula R, Jatoi A, Foster NR, et al (2008). Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E. Clin Med Oncol, 2, 223-5.
8 Kelsey CR, Chino JP, Willett CG, et al (2007). Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys, 69, 770-6.   DOI   ScienceOn
9 Langer CJ, Harris J, Horwitz EM, et al (2007). Phase II study of low-dose paclitaxel and cisplatin in combination with splitcourse concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol, 25, 4800-5.   DOI   ScienceOn
10 Mirinezhad SK, Somi MH, Jangjoo AG, et al (2012). Survival rate and prognostic factors of esophageal cancer in east Azerbaijan province, North-west of Iran. Asian Pac J Cancer Prev, 13, 3451-4.   DOI   ScienceOn
11 Li BS, Gong HY, Huang W, et al (2011). Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma. Dis Esophagus, b, 251-7.
12 Liu JL, Zhou LL, Cai MH, et al (2009). Observation on the short-term effect of nedaplatin plus tegafur in the treatment of advanced esophageal carcinoma. J Pract Oncol, 24, 515-6.
13 Jiang C, Liao FX, Rong YM, et al (2014). Efficacy of taxanebased regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer. Asian Pac J Cancer Prev, 15, 5493-8.   DOI
14 Orditura M, Galizia G, Napolitano V, et al (2010). Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Cancer Invest, 28, 820-7.   DOI
15 Polee MB, Eskens FA, van der Burg ME, et al (2002). Phase II study of biweeklyadministration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer, 86, 669-73.   DOI
16 Safran H, Dipetrillo T, Akerman P, et al (2007). Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys, 67, 405-9.   DOI   ScienceOn
17 Seidman AD, Hochhauser D, Gollub M, et al (1996). Ninetysix hour paclitaxel infusion after progression during taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol, 14, 1877-84.
18 Shade RJ, Pisters KM, Huber MH, et al (1998-1999). Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs, 16, 237-43.
19 Tsuya A, Kaneda K, Okano S, et al (1968). Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer. Gan No Rinsho, 14, 340-52.
20 Seiwert TY, Connell PP, Mauer AM, et al (2007). A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res, 13, 515-22.   DOI
21 Tang WR1, Fang JY, Wu KS, et al (2014). Epidemiological characteristics and prediction of esophageal cancer mortality in China from 1991 to 2012. Asian Pac J Cancer Prev, 15, 6929-34.   DOI
22 Wang J, Yu JM, Jing SW, et al (2014). Relationship between EGFR over-expression and clinicopathologic characteristics in squamous cell carcinoma of the esophagus, a metaanalysis. Asian Pac J Cancer Prev, 15, 5889-93.   DOI
23 Wang T, Zhang SF, Wang L (2010). A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer. Nat Med J China, 90, 1986-8.
24 Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6.   DOI   ScienceOn
25 West HL, Crowley JJ, Vance RB, et al (2005). Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714) : a Southwest Oncology Group study. Ann Oncol, 16, 1076-80.   DOI   ScienceOn
26 Wong R, Malthaner R (2003). Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev, 1, CD002092.